Background/Aims: Circulating (serous or plasmic) long non-coding RNA (lncRNA) as biomarkers for predicting the diagnosis or prognosis of human disease have been well documented. Due to the sensibility or specificity limitation of Alpha Fetoprotein (AFP), a cluster lncRNAs were revealed as fingerprints for hepatocellular carcinoma (HCC). In this study, we enrolled all the reported circulating lncRNAs in HCC as candidate targets and examined in an independent cohort. Methods: The candidate lncRNAs were determined by qRT-PCR divided into training and validation sets. The risk score analysis was employed to evaluate the potential diagnosis ability of the lncRNAs independently or combining with AFP value. The receiver operating characteristic curve (ROC) was applied for presentation of sensibility or specificity. Results: Among the ten candidate circulating lncRNA, LINC00152, RP11-160H22.5, XLOC014172 and LOC149086 were screened with significant difference in training set. Further investigation in validation set indicated LINC00152, RP11-160H22.5 and XLOC014172 might be the fingerprints for HCC comparing with chronic hepatitis (CH) patients or healthy controls. The risk score analysis revealed the combination of three lncRNAs with AFP could distinguish the HCC from either CH or healthy control with the area under curve value (AUC) of 0.986 and 0.985, respectively. Conclusion: The three lncRNAs may act as novel biomarkers for acting as fingerprint in HCC combining with AFP.
Introduction
As one of the most common life-threatening malignancies worldwide, hepatocellular carcinoma (HCC) was estimated to cause 748, 300 new liver cancer cases and 695, 900 cancer deaths worldwide per year and nearly half of these cases and deaths were estimated to take place in China [1] [2] [3] . Although the major risk factors have been identified, including hepatitis C (HCV) and B virus (HBV) infection, toxins (aflatoxin B1), chronic alcohol abuse and nonalcoholic fatty liver disease [4] [5] [6] . The early diagnosis of HCC still remain a crucial issue currently due the low sensibility or specificity limitation of Alpha Fetoprotein (AFP) [7] [8] [9] . Hepatitis B virus (HBV) infection is an important factor for HCC occurrence. The association between HBV and HCC has been demonstrated by multiple epidemiological studies: High HBV prevalence may result in a high frequency of occurrence of HCC, and the risk of HCC in HBV carriers is significantly increased compared with that of non-carriers [10] . Thus, the occurrence of hepatocellular carcinoma (HCC) is decreased but not eliminated. The molecular mechanisms as well as the biomarkers for HCC that contributing to the occurrence and development of HCC remain elusive, hindering the development of clinic diagnostic or therapeutic approaches.
To date, the long non-coding has been proved as important role in the pathogenesis of human disease including HCC [11] [12] [13] . LncRNAs were considered as non-protein-coding transcripts longer than 200 nucleotides and widely expressed in various organs and tissues of the body [14] [15] [16] . Functional lncRNA was involved in various cancer biological processes, such as proliferation, apoptosis, invasion and metastasis through modulation of chromatin remodeling, epigenetics modification, regulation of gene transcription, post-transcriptional mRNA processing, protein function and localization, and intercellular signal transduction regulation [17] . Many previous studies showed that lncRNAs might be as biomarkers in multiple cancers. For example, The MD-miniRNA, derived from MALAT-1, has been explored, and was available for clinical detection for human prostate cancer [18] . The fragment of Linc00974 could was also detectable and might improve the prognosis of HCC by comparing with CYFRA-21-1 [19] .
In this study, we conducted our experiment based on the identified lncRNAs which was certain diagnostic value in HCC according to previous report. We enrolled ten candidate lncRNAs for screening. We hypothesized that these HCC-related lncRNAs might be utilized to detect and early monitor HCC by combining with the well-known maker AFP. We aimed to explore the potential lncRNA acting as fingerprint for the early identification of HCC.
Materials and Methods
Samples and Screening phase 100 fresh HCC plasma samples were obtained from the patients received therapy at Huai'an First People's Hospital. Controls were from healthy volunteers without any health problems during their health check-ups at the Huai'an First People's Hospital. The study was approved by our Institutional Ethics Committee of Huai'an First People's Hospital. All patients provided their written informed consent to participate in the study. The HCC patients were confirmed by the histopathological examination. Peripheral blood samples of patients were collected before surgery. Blood samples were collected in a separate vacuum cube, followed by centrifugation at 3, 000 rpm for 10 min. All samples were stored at −80°C until further analysis. The clinical characteristics of all patients are summarized in Table 1 . All candidates were tested in an independent cohort of 20 plasma samples obtained from patients regarding as training set. The rest 80 samples was labelled as validation set randomly. 
Quantitative real-time PCR (qRT-PCR)
Total RNAs were obtained from plasmic samples using TRIzol reagent as described by the manufacturer (Invitrogen Life Technologies Co, Carlsbad, CA, USA). For mRNA detection, total RNAs (500ng) were reverse transcribed using the reverse transcription kit (Takara, Tokyo, Japan). The quality of RNA samples was assessed by a UV spectrophotometer (Bio-Rad, Hercules, CA, USA), and the 260/280nm absorbance ratio of samples were limited to 1.8-2.0. QRT-PCR was performed by using ABI Prism 7900HT (Applied Biosystems, CA, USA). The expression levels of these candidates were analyzed in all samples, and comparative 2 -ΔΔCt method algorithms were used to analyze the difference between patients and health controls.
Risk score analysis
Risk score analysis was performed to evaluate the associations between the concentrations of the plasma lncRNA expression levels. The upper 95% reference interval of each lncRNA value in controls or CH group was set as the threshold to code the expression level of the corresponding lncRNA for each sample as 0 and 1 in the training set. A risk score function (RSF) to predict HCC group was defined according to a linear combination of the expression level for each lncRNA. For example, the RSF for sample i using information from three lncRNAs was: rsfi=∑3j-1Wj.sij. In the above equation, sij is the risk score for lncRNA j on sample i, and Wj is the weight of the risk score of lncRNA j. The risk score of three lncRNAs was calculated using the weight by the regression coefficient that was derived from the univariate logistic regression analysis of each lncRNAs. Samples were ranked according to their RSF and then divided into a high-risk group, representing the HCC patients, and a low-risk group, representing the predicted control individuals or CH patients. Frequency tables and ROC curves were then used to evaluate the diagnostic effects of the profiling and to find the appropriate cutoff point, and to validate the procedure and cutoffs in the next validation sample set.
Statistical analysis
Data were presented as mean (S.E.M.). The Student's t-test and Mann-Whitney unpaired test analysis of variance were used to evaluate statistical differences between patients and controls. Analysis of area under the ROC curve (AUC) was used to estimate the effectiveness of lncRNA. Statistical analysis was performed using softwares of STATA 10.0 and GraphPad prism. In all cases, P<0.05 was considered to be significant. All P values were two-sided.
Results

Screening the HCC-associated lncRNAs in training set
The ten candidate circulating lncRNAs was enrolled including DANCR, SPRY4-IT1, HULC, LINC00152, LINC00974, MALAT1, LncRNA-CTBP, RP11-160H22.5, XLOC014172 and LOC149086. The candidates were first detected in the 20 plasma samples as training set. We found that the four lncRNAs (LINC00152, RP11-160H22.5, XLOC014172 and LOC149086) were significant different in HCC patients comparing with either patients with CH or healthy control (Fig. 1) 
Confirming the candidate biomarker in validation set
The following investigation was conducted by detecting the expression of the four lncRNAs in the validation set. As presented in Fig. 2, LINC00152 , RP11-160H22.5 and XLOC014172 were confirmed in the larger individual samples indicating as the potential biomarker for predicting HCC, while the LOC149086 present no significant difference.
Diagnostic potency prediction by risk score analysis
Researcher has reported the three lncRNAs might be potential biomarkers for HCC; however, they only focused on predictive value of these lncRNAs through healthy controls, no evidence was given for these lncRNAs to predict the HCC from patients with CH. This might be a useful factor for clinical application. Here, in this study, to validate the accuracy and specificity of these 3 lncRNA as a HCC potential signature, the risk score formula was applied to assess the diagnostic value of the three lncRNAs profiling system by combining with AFP. First, we analyzed the predictive value of these three lncRNA and AFP comparing with the healthy control. The risk score of each plasma sample in the training set was calculated, as the basis of their risk scores and a set cut off, plasma samples were then divided into a high-risk group, representing the possible HCC group, and a low-risk group, representing the predicted controls. At the optimal cutoff value (Value=8.12) with the value of sensitivity + specificity considered to be maximal, the positive predictive value (PPV) and negative predictive value (NPV) was 70% and 80% in the training set, respectively. Similarly, when the same cutoff value was applied to calculate the risk score of samples in the larger validation sets, the PPV and NPV were 88%, 81%, respectively (Table 2) . ROC curve analysis was used to evaluate the predicting diagnosis value of lncRNAs and AFP for HCC. Areas under the ROC curves of the validated three lncRNAs signature were 0.869, 0.884 and 0.759, respectively while the combination of the three factors with AFP possessed a moderate ability for discrimination between HCC patients and controls with an area under the ROC curve of 0.986 (Fig. 3A) . The similar strategy was applied for predicting the HCC diagnostic value of lncRNAs by comparing with patients with CH. At the optimal cutoff value (Value=5.88) with the value of sensitivity + specificity considered to be maximal, the positive predictive value (PPV) and negative predictive value (NPV) was 65% and 80% in the training set, respectively. Similarly, when the same cutoff value was applied to calculate the risk score of samples in the larger validation sets, the PPV and NPV were 87%, 80%, respectively (Table 3) . ROC curve analysis was used to evaluate the predicting diagnosis value of lncRNAs and AFP for HCC. Areas under the ROC curves of the validated three lncRNAs signature were 0.826, 0.859 and 0.735, respectively While the combination of the three factors possessed a moderate ability for discrimination between HCC patients and controls with an area under the ROC curve of 0.985 (Fig. 3B) .
Discussion
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor with the third leading cause of cancer-related death in the world [20, 21] . HCC is chartered by high malignancy, easy invasion especially towards intrahepatic invasion and frequent reoccurrence after surgical resection [22] . Increasing evidence indicated lncRNAs as biomarker for predicting survival and metastasis or diagnosing in multiple diseases which was confirmed contributing to many biological processes through diverse mechanisms [11] . Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry
Mechanism study have been described for selected lncRNA involved in liver diseases include widely diverse functions such as DNA imprinting, X inactivation, DNA demethylation, gene transcription and generation of other RNA molecules [23] . Not only the miRNA, but also the lncRNA have been annotated acting as biomarkers in predicting the feature of tumor. For example, circulating serum lncRNA RP11-445H22.4 as biomarker for the detection of breast cancer [24] . In this study, the ten lncRNA was enrolled as candidates based on the important function reported previously. These tissues different expressed lncRNA might present an alternated level in patients' bodily fluid. Research has speculated that the aberrant expressed circulation lncRNAs might be derived from the tumor. Thus, we examined the expression of the 10 lncRNAs in patients and healthy control. Accordingly, Long noncoding RNA DANCR could increase stemness features of hepatocellular carcinoma by derepression of CTNNB1 [25] . Overexpression of the long noncoding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma [26] . HULC and Linc00152 Act as Novel Biomarkers in Predicting Diagnosis of Hepatocellular Carcinoma [27] . A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma [19] . Long NonCoding RNA MALAT1 Regulates ZEB1 Expression by Sponging miR-143-3p and Promotes Hepatocellular Carcinoma Progression [28] . The lncRNA-CTBP has also been identified had high sensitivity and specificity for discriminating HCC from healthy controls and also from CH patients [29] . Tang et al. also published the results that lncRNAs might act as biomarker for the diagnosis of HCC from healthy control and CH patients [30] . In this study, by employing a multiple screening phase, we found that LINC00152, RP11-160H22.5, XLOC014172 and LOC149086 were screened with significant difference in training set. Further investigation in validation set indicated LINC00152, RP11-160H22.5 and XLOC014172 might be the fingerprints for HCC comparing with patients with chronic hepatitis (CH) or healthy controls.
For the biomarkers screening study in HCC, researchers has identified multiple factors that might be the potential fingerprint; however, most of this study was conducted by comparing the expression of these lncRNAs in a case-control study. The control group enrolled was healthy volunteers. This kind of biomarker might be useful for distinguish the HCC patients from healthy human; however, the HCC patients was developed from HBV positive patients, most of them might be suffering with CH or liver cirrhosis. Biomarkers for predicting HCC from patients with CH or liver cirrhosis might be useful for clinical approach especially for the early diagnosis of HCC.
Researchers has found that cigarette smoke exposure will cause an aberrant expression profiling of lncRNA in lung cancer associated cell lines [31] . Based on the different cigarette exposure in the three groups, we thought it was necessary to identify the expression of circulating lncRNA in patients with the cigarette exposure or not. This might give us a novel point both for the pathogenesis and diagnosis of HCC.
Conclusion
We identified three lncRNAs, LINC00152, RP11-160H22.5 and XLOC014172, as the potential biomarker for the tumorigenesis prediction of HCC from both healthy controls and patients with CH combining with AFP in this study. These factors might serve as a better biomarker for the early diagnosis of HCC especially for patients with HBV infection background.
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